Journals / Selçuk Tıp Dergisi / 2009 / Cilt: 25 - Sayı: 4

Retinopathy of prematurity: Current understanding and future prospects

Prematürite retinopatisi: Güncel yaklaşım ve yeni açılımlar

Pages
223–233
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Recent technical and medical improvements may induce major changes at the screening and treatment protocols of PR.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Retinopathy of prematurity (ROP) is a potentially blinding disease.
📊
Key Findings & Data:Increased number of Newborn Intensive Care Units leads to survive of incerased number of immature babies which in turn leads to increased number of premature infants to be screened and eyes to be treated.
💡
Conclusion & Impact:Recent technical and medical improvements may induce major changes at the screening and treatment protocols of PR.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Retinopathy of prematurity (ROP) is a potentially blinding disease. ROP continues to be a leading cause of blindness of newborn in areas of the world that provide neonatal intensive care services to premature newborns. The aim of this review is to evaluate the new technical improvements and treatment modalities under current data. Increased number of Newborn Intensive Care Units leads to survive of incerased number of immature babies which in turn leads to increased number of premature infants to be screened and eyes to be treated. Although the current gold standart of screening method is examination by an experienced opthalmolog with binocular indirect ophthalmoscopy, a new debate arose that claims digital retinal photographs may be taken and evaluated in the remote reading centers by experienced ophthalmologists. On the other hand intravitreal injection of single dose of anti-VEGF may replace the more destructive cryotherapy and laser at the treatment aspect. Recent technical and medical improvements may induce major changes at the screening and treatment protocols of PR.

Özet

Prematurite Retinopatisi kör edici potansiyele sahip bir hastalıktır. Dünyanın yenidoğan yoğun bakım hizmeti sunulan bölgelerinde çocuk körlüklerinin başta gelen sebebi olmaya devam etmektedir. Bu derlemedeki amacımız güncel bilgiler ışığında PR tarama ve tedavisindeki yenilikleri değerlendirmektir. Yenidoğan yoğun bakım unitelerinin yaygınlaşması daha fazla sayıda ve daha immatür bebeklerin yaşatılmasına olanak sağlamaktadır. Bu da taranması gereken prematür infant sayısını ve tedavi edilmesi gereken göz sayısını artırmaktadır. Bugüne kadar muayeneyi deneyimli bir göz hekiminin hasta başında binoküler indirekt oftalmoskop ile yapması gerekliliği savunulurken artık çekilen renkli dijital fotoğrafların belirli merkezlerde göz hekimleri tarafından değerlendirilebileceği tartışılmaktadır. Tedavi cephesinde ise daha destrüktif olan kriyoterapi ve laser tedavisi yerine göz içine bir defa enjekte edilecek anti-anjiyojenik ilaçların kullanıma girmesi mümkün görünmektedir. Yaşanan teknolojik ve medikal gelişmeler prematürite retinopatisinin tarama ve tadavi şemalarında yakın zamanda köklü değişiklikler yapabilir.

🔖

Cite This Article

KERİMOĞLU, H., ÖZTÜRK, T. B., ÖRS, R. (2009). Retinopathy of prematurity: Current understanding and future prospects. Selçuk Tıp Dergisi, Cilt: 25 - Sayı: 4, 223–233. https://ajindex.com/articles/319523

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. Am J Ophthalmol 1942;25:203-204
  2. Quiram PA, Capone A Jr. Current understanding and management of retinopathy of prematurity. Curr Opin Ophthalmol. 2007;18:228-34
  3. Good WV, Hardy RJ, DObson V, et al. Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the Early Treatment for Retinopathy of Prematurity Study. Pediatrics 2005;116:15-23
  4. McLoone E, O’Keefe M, Lanigan B. Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: Results of Goldmann Perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus 2007; 144:170–173
  5. Quinn G, Dobson V, Davitt B, et al. Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology 2008; 115:1058–1064
  6. Chen J, Smith L. Retinopathy of Prematurity. Angiogenesis 2007; 10:133–140
  7. Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr. 2009;21:182-7
  8. Charles BJ, Ganthier R, Appiah AA. Incidence and characteristics of retinopathy of prematurity in a low-income inner-city population. Ophthalmology 1991;98:14–17
  9. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Prognostic factors in the natural course of retinopathy of prematurity (Palmer EA, Schaffer DB, Plotsky DF: The Cryotherapy for Retinopathy of Prematurity Cooperative Group). Ophthalmology 1993;100:230–273
  10. Phelps DL, Brown DR, Tung B, et al. 28-Day survival rates of 6676 neonates with birth weights of 1250 grams or less. Pediatrics 1991;87:7–17 11. Ober RR, Palmer EA, Drack AV, Wright KW. Retinopathy of Prematurity. Wright KW,Spiegel PH, Thompson LS, eds. Handbook of Pediatric Retinal Disease. New York: Springer, 2006,pp.284-349
  11. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, Tung B. Incidence and early course of retinopathy of prematurity. Ophthalmology 1991; 98:1628-40 13. Phelps DL. Retinopathy of Prematurity.In: Martin RJ, Fanaroff AA, Walsh MC (eds). Fanaroff and Martin’s Neonatal-Perinatal Medicine Diseases of the Fetus and Infant, 8th ed, Philadelphia: Mosby, 2006, pp.1747-52
  12. Shohat M, Reisner SH, Krikler R, et al. Retinopathy of prematurity: Incidence and risk factors. Pediatrics 1983;72:159–163.